chapteR 1: pRevalence of hypeRtension
Cardiovascular disease has become the world's leading cause of death. The total mortality rate of cardiovascular disease in China has increased from 2400/million in 2004-2718/million in 2012. [1, 2] Previous studies have shown that hypertension is an important risk factor for cardiovascular and cerebrovascular diseases. [2] [3] [4] The results of the Global Burden of Disease Study 2010 showed that the risk factors affecting the global burden of disease in hypertension in the 1990s jumped from fourth to first [4] in China. The prevalence rate of hypertension increased year by year, and the number of patients continues to increase. Although the control status of hypertension has improved, it remains at a low level. Prevention and treatment of hypertension are urgent.
the pRevalence and tRend of hypeRtension in china

Hypertension status quo
High blood pressure is defined as the systolic blood pressure exceeding 140 mmHg and/or diastolic pressure 90 mmHg 3 day of the same period without the use of antihypertensive drugs. History of hypertension and antihypertensive drugs are currently being used, although blood pressure is lower than 140/90 mmHg also diagnosed with hypertension. [5] China Nutrition and Health Survey 2002 (CHNS) [6] showed that the hypertension prevalence rate was 18.8% in people 18 years of age and older in China. Nearly 153 million people were suffering from hypertension among whom 20.2% were male and 18% female. [7] The latest report on the status of nutrition and chronic diseases in China (2015) showed that the prevalence rate of hypertension among people 18 years of age and older was 25.2% in 2012 in China. [1] There are notable differences in prevalence of hypertension between different regions, cities and villages, gender, and ages. From the regional distribution, the prevalence rate of hypertension in eastern China is the highest (32.6%), followed by the Northeast (31.8%), with the lowest in the Southwest (20.1%). [8] From the perspective of urban and rural distribution, in people 15 years of age and older, the prevalence rate of hypertension in medium-sized cities was higher than that of rural areas (31.3% >29.7%) in the Heilongjiang Province. [9] In the Beijing area, 18-79 year olds in the city showed a higher prevalence rate of hypertension compared to rural areas (35.6% >34.9%); however, the gap between urban and rural areas has narrowed in recent years. [10] From the perspective of gender and age, in 2012 in the Henan Province hypertension, the prevalence rate was 24.9% in 15-74-year-old people, among them male (26.6%) and women (23.5%). The overall prevalence rate increased with age; however, the prevalence rate of men under 55 years of age was higher than that of women. The prevalence rate of women older than 55 years of age was more than that of men. [11] In 2010, the prevalence rate of hypertension was 22.59% in 17,437 residents over the age of 18 in the south of China, among whom the rate for males (23.36%) was higher than females (21.77%). The overall prevalence rate increased with age; however, the prevalence rate of men between 18 and 49 years of age was higher than that of women, and the prevalence of women older than 50 years of age was greater than men. In addition, with the increase of age, the risk of hypertension among people 18-44 years of age has increased 8.53 times that of people 60 years of age and older. [12] 
Trend of hypertension prevalence
In the past 50 years, China has carried out the four national surveys of hypertension in 1958-1959, 1979-1980, 1991, and 2002 , respectively. The results showed that in people 15 years of age and older the prevalence rate of hypertension was 5.1%, 7.7%, 13.6%, and 17.6% [6] [ Figure 1 ]. The results of the CHNS showed that the prevalence of hypertension in China increased from 14.5% in 1991 to nearly 21.4% in 2009, with an absolute increase of 6.9%. [13] The results of a longitudinal cohort study from the 1991 to 2011 Chinese health and nutrition survey also shows that in China the prevalence rate of hypertension increased from 23.4% to 28.6% including changes in men and in elderly patients with the most obvious. [14] The 2015 National Health and Family Planning Commission of the People's Republic of China released data suggesting that in 2012 the country's adult hypertension prevalence rate was 25.2% in people 18 years of age and older. [1] On the whole, the prevalence of hypertension in China is higher in men than in women, with the northern region higher than the southern and cities higher than rural areas. However, the gap between urban and rural areas is gradually narrowing. The prevalence of hypertension in China is increasing year by year as suggested by this timeframe. In summary, men, the elderly and rural areas remain the focus of hypertension prevention and control efforts in China.
Risk factoRs of hypeRtension in china
Traditional risk factors for hypertension include high sodium and low potassium diets, overweight and obesity, alcohol consumption, mental stress, family history of hypertension, and lack of physical activity. Domestic scholars have shown that smoking, drinking, diabetes, and dyslipidemia increased the risk of hypertension. [12] Recent studies have also been conducted on other risk factors such as air quality (fog and haze) and hypertension. 1. Sodium-potassium intake and hypertension: intake of sodium was positively correlated with blood pressure and prevalence of hypertension, while potassium salt intake was negatively correlated with blood pressure. The results of a survey from 19,519 community residents 35-91 years old in 2008 in Shanghai showed that daily salt intake was <12 g; the prevalence rate of hypertension was 44.11% -higher than that of 12 g; the prevalence rate of hypertension was 54.54%; and the prevalence rate of hypertension increased by 10.43%. [15] According to data reported in the salt reduction and hypertension control project in Shandong Province of 2011, the urinary sodium levels at 24 h in 1948 adults were divided into five groups ranging from low to high. The results showed that residents with the highest salt intake had the highest risk of high blood pressure, an increase of 30% compared with the lowest group. [16] The INTERSALT Study on salt and hypertension analyzed data on 10,079 adults from 32 different countries in 52 populations including 600 Chinese people from Beijing, Nanning, and Tianjin. This study found that the median of 24 h urine sodium increased per 100 mmo1/day, systolic blood pressure increased by a median of 5-7 mmHg, and diastolic blood pressure increased by a median of 2-4 mmHg. [17] The results of the INTERMAP study of salt and blood pressure involving four countries and international collaboration showed that the index reflects the ratio of sodium/potassium intake in 24 h was approximately 6, which was far higher than that western countries 2-3. [18] This partly explains why the prevalence of obesity is much lower in China compared to western countries; however, the prevalence of high blood pressure remains at a higher level 2. Overweight and obesity: A 10-year prospective study of overweight and obesity showed a baseline normal weight cumulative incidence of hypertension was 36.3%. The overweight and obesity cumulative incidence of hypertension were 55.3% and 69.2%, respectively. [19] Data from the 2011-2012 study of 1870 subjects in Ji'nan showed that overweight, obesity, and central obesity were all risk factors for hypertension; however, the effect of obesity on hypertension was the highest [20] 3. Drink wine: The study in Kailuan looked at 32,389 adults without hypertension, after 4 years of follow-up, and daily alcohol consumption (calculated daily alcohol intake) for 0.1-24 g, 25-49 g, 50-99 g, 100-149 g, and over 150 g. The cumulative incidence of hypertension was 25.0%, 28.8%, 30.10%, 37.1%, 40.1%, and 42.5%. [21] With the increase in alcohol consumption, the prevalence of hypertension is also rising. In 2008, a study in Suzhou showed that the prevalence of hypertension increased with the increase in alcohol consumption, as shown in Figure 2 [22] 4. Family history: The prevalence of hypertension was significantly increased with a family history of hypertension. According to a 2008 survey, on the prevalence of family history of hypertension among 19,519 community residents between 35 and 91 years of age in Shanghai, the prevalence rate of hypertension was 51.3%. The rate among residents with no family history of hypertension was 39.0% [15] 5. Air quality (fog and haze): In addition to the above traditional risk factors, the effect of air quality (fog and haze) on the prevalence of hypertension continues to raise concern. 10 , SO 2, and O 3 in the air increased, and the risk of hypertension increased. [23] The data on the correlation between PM and hypertension are still unclear.
awaReness Rate, tReatMent Rate, and contRol Rate of hypeRtension in china
The awareness rate, treatment rate, and control rate of hypertension patients Overall, the control of hypertension in China is still at a low level; however, there has been a trend of improvement. The national hypertension survey in 2002 showed that the awareness rate, treatment rate, treatment control rate, and control rate of hypertension were 30.2%, 24.7%, 25%, and 6.1%, respectively, for people 18 years of age and older. [6] Results from the 13 Province survey of 50,171 people 18 of age and older in [2009] [2010] showed that the rates of hypertension awareness, treatment rate, control treatment rate, and control rate were 42.6%, 34.1%, 27.4%, and 9.3%, respectively. [24] The results of the survey in different regions of the country suggested significant differences in the awareness rate, treatment rate, and control rate of hypertension among different populations [ Table 1 ]. [10, 12, [25] [26] [27] [28] The change trend of awareness rate, treatment rate, and control rate of hypertension
The CHNS conducted surveys of awareness, treatment, and control rates of hypertension among people 18 years of age and older in nine provinces in the past 1991 and 2009 years. The results showed an upward trend in the awareness rate, treatment rate, and control rate of hypertension, but still at a low level, as shown in Figure 3 . [13] Another at the age of 35-59 years old adult data analysis results showed that the rates of hypertension awareness, treatment, and control rates were 32.4%, 22.6% from 1992 to 1994 and 2.8% increased to 48.4% in 2004-2005, 38 .5%, and 9.5%. [29] Cognition and practice of hypertension awareness and control
The HAPPEN study of attitudes and needs on hypertension in China tertiary hospitals published by the European Society of Hypertension showed that 90% of the doctors told patients with hypertension [30] diagnosis and numerical control of blood pressure when it reached the target value, but only 67% the patients know their blood pressure target value, suggesting that the doctor also overestimated the awareness rate on blood pressure in patients with the target value. Doctors think they admissions of patients 70% patients with blood pressure can be achieved, but in fact, according to the blood pressure measurements for 2 weeks, the blood pressure of the patients know, only 31% patients reached target blood pressure. The results showed that in the daily management of hypertension, the Chinese doctors overestimated the target blood pressure awareness rate and the control rate of blood pressure.
Current situation and problems
1. The prevalence rate of hypertension in China is still on the rise, and the number of patients is increasing, but the rate of increase has slowed. The prevalence rate of hypertension in people 18 years of age and older in 2012 was 25.2%. Although the awareness rate, treatment rate, and control rate of hypertension in China have been improved, they are still at a low level 2. The main risk factors of hypertension were high salt, overweight, obesity, and excessive drinking 3. The prevalence of hypertension was still high in the north and low in the south 4. There were some differences between the doctors and patients in the cognition and practice of target blood pressure and blood pressure control. 
Molecular epidemiological characteristics of hypertension
Hypertension is related to heredity. The risk of hypertension in first-degree relatives was 2 times higher than that of the general population.
Familial aggregation of hypertension suggests that blood pressure is affected to some extent by genetic factors. The genetic mechanism of hypertension is complex, which is caused by the interaction of multiple genes and environmental factors.
Data from twin studies in the Chinese population suggest that genetic factors account for 30%-46%. [31] The linkage and candidate gene association study of the 1990s found at least 150 of primary hypertension and blood pressure variability associated with susceptibility loci, involving the renin-angiotensin system, wake up with solid sympathetic nerve system, endothelin, Lena skin, kallikrein-kinin system, and ion channels of the skin. [32] [33] [34] [35] [36] In 2009-2011 study, under the cooperation of China, Japan, Korea, and other East Asian countries, six blood pressure-related susceptibility genes, or regions were identified. The analysis published in 2015 China crowd large-scale, multistage hypertension genome-wide association (GWAS), gene chip were detected in 11,816 cases of individuals, and repeated verification was conducted in 69,146 samples. 19 susceptibility genes associated with blood pressure and hypertension were identified and 4 newly identified four genetic susceptible regions or genes (CACNA1D, CYP21A2, HLA-B, and MED13 L). In the SLC4A7 region, it was found the Chinese population-specific susceptibility locus rs820430. It was confirmed that 14 genetic susceptibility loci previously reported by other countries were associated with blood pressure and hypertension in the Chinese population. [37] The risk score of the 19 genetic variants, with an increased genetic risk score, systolic blood pressure (P = 4.73 * 10-67), and diastolic blood pressure (P = 2.03 * 10-69) significantly increased. [37] GUCY1A3 gene variants are associated with blood pressure in Chinese and European populations. GUCY1A3 gene encoding soluble guanylate cyclase (sGC) is a key enzyme in the NO-cGMP pathway, which has been used in clinical trials for the treatment of pulmonary hypertension and pulmonary heart disease. The GWAS study provides an important theoretical basis for the treatment of hypertension and other cardiovascular diseases with sGC activator.
Major environmental factors affecting blood pressure variability include the intake of sodium and potassium in the diet. Different individuals showed a different blood pressure response to dietary sodium and potassium intake, which are called salt sensitivity and potassium sensitivity, respectively. The research results showed that the sensitivity of blood pressure to sodium and potassium also had obvious genetic heterogeneity.
The Genetic Epidemiology Network of Salt Sensitivity (GenSalt) in the China northern Han people performed a dietary low salt (sodium chloride), high salt, and high salt potassium intervention experiment.
In this study, they investigated the genetic mechanism of more than 30 genes including renin-angiotensin system and endothelin and ion channel and found a large number of related genes, such as 11-, is a 1-sterol dehydrogenase, mineralocorticoid receptor, and endothelin 1 which are related with salt sensitive and/or potassium sensitivity. [38, 39] A genome-wide association analysis found eight new sensitive potassium salt sensitive susceptible genes or regions identified as PRMT6, CDCA7, PIBF1, ARL4C, IRAK1BP1, SALL1, TRPM8, and FBXL13. These results provide important clues for studying the molecular mechanism of dietary sodium and potassium regulating blood pressure. A 7.5-year follow-up showed an increased risk of high blood pressure with an increasing genetic risk score. According to the genetic risk score, the patients were divided into four groups. Compared with the lowest group, the risk of hypertension in the other three groups increased by 1.24, 1.55, and 1.92 times, respectively, [40] according to a study on molecular epidemiology in China.
Current status of hypertension in urban communities
1. Prevalence of hypertension in different urban communities.
On the basis of a national survey of hypertension, various cities in the country have also carried out a survey of the prevalence of hypertension, the specific data of which are shown in Table 2 2. The trend of the prevalence of hypertension in urban communities. Figure 4 ]. [45] Overall, the prevalence of hypertension in rural areas was higher; however, the awareness rate, treatment rate, and control rate were at a low level. With the passage of time, the prevalence of hypertension in rural areas increased significantly, and the gap between urban and rural areas gradually narrowed. In addition, rural areas of poor medical foundation, low awareness of health, and therefore should pay more attention to the problem of hypertension in rural areas. 
Current situation of hypertension in ethnic minority areas
China is a multi-ethnic country comprised different nations. Due to the differences in genetic structure, living environment, living customs, economic culture and religious belief, the etiology, pathogenesis and epidemiological characteristics of hypertension are diverse and complex.
According to the China Nutrition and Health Survey in 2002, Tibetan, Manchu, and Mongolian had the highest incidence of hypertension with national standardized prevalence rates of 24.7%, 20.5% and 17.6%, respectively. These were higher than that of the Han population (16.2%), and the prevalence rate of hypertension among Hui, Miao, Zhuang and Buyi people was lower than that of the Han nationality, which was 16%, 7.7%, 11.8%, respectively. [53] In addition, epidemiological survey of Hypertension Center of the Xinjiang Uygur Autonomous Region People's Hospital of 15,892 cases over 30 years old in Xinjiang minority patients with hypertension were found in Xinjiang, Kazak, Uygur, Mongolian, and Han nationality in the incidence rate of hypertension were 55%, 52%, 42%, and 40%. [54] A sample survey of 986 Guangxi adults between 40 and 89 years of age found that the prevalence rates of hypertension among the Baikuyao and Han nationalities were about 21.9% and 28.9%, respectively. [55] An epidemiological survey of 2133 cases of hypertension in Yunnan adults 50 years of age and older showed that the prevalence of hypertension in the Bai nationality was 42.1%. [56] Further data analysis showed that the prevalence of hypertension among the same ethnic groups in different regions also showed great differences. The data showed that the incidence of hypertension among Tibetans in Tibet and Gansu was 51.2% and 24.6%, respectively. [57, 58] Due to the unique characteristics of minority areas throughout China, it is critical to actively explore the various patterns of hypertension to effectively promote its prevention, control, and treatment. cuRRent situation and pRobleMs 1. Hypertension is affected by the combined action of genetic factors and environmental factors. Genetic factors to some extent facilitate the role of environmental factors so that the role of amplification. The GenSalt study found eight genes related to hypertension and salt. The GWAS study found four genetic susceptibility regions or genes and confirmed that the genetic susceptibility loci of 14 previously reported by foreign countries were associated with blood pressure and hypertension in the Chinese population. The interaction between these genes and the environment play an important role in the occurrence and development of hypertension in China 2. Notable differences in the prevalence rates of hypertension are seen between urban and rural areas and different ethnic groups. The prevalence rate of hypertension is still higher in the North and lower in the South. The rural prevalence rate is as high as 51%, has increased quickly, and a narrowing trend between urban and rural areas has been noted.
Recommendations
1. Breakthroughs in current science to identify genetic characteristics associated with hypertension have led to strategies that provide for precise individualized treatment. Based on the conditions of specific regions, genetic characteristics should be examined when treating hypertensive populations in need 2. The medical establishment in rural areas is ill-equipped and less attentive to prevention and control strategies for hypertension. Under the participation of the government, major hospitals and rural grassroots health institutions, a collaborative system is needed to make full use of available medical resources to improve the level of diagnosis and treatment of hypertension in rural areas 3. Due to the myriad scenarios and variables associated with various ethnicities and minority areas, the pattern and means of prevention and treatment of hypertension in minority areas should be actively explored to more effectively promote the work of prevention and treatment of hypertension in the minority areas of China.
chapteR 3: the disease buRden of hypeRtension
Hypertension can not only damage the physical health and life quality of patients but also lead to great economic burden on individuals, families, and the whole society with the rising medical costs. According to the Global Burden of Disease 10 .667 in every 100,000 population in China, 78.3% of which was due to disability and 21.7% was due to dying early. [59] the econoMic buRden of hypeRtension
The economic burden of hypertension is defined as economic loss due to hypertension, which includes direct and indirect economic burden.
Direct economic burden includes the direct medical costs on treating hypertension including registration fees, medication, beds, diagnosis and operation, and direct nonmedical costs including nursing, fees, nutrition, and transportation. From the social aspect, the direct medical costs not only include the patient out-of-pocket expenses but also medical insurance costs often calculated by currency. Chinese patients often purchase their anti-hypertension drugs in pharmacies, and thus, the costs of these medications are defined as direct medical costs. Indirect economic burden includes the health loss due to the illness and death caused by hypertension. The health loss caused by hypertension can be estimated with the human resource model including the loss of income due to the illness or death. The indirect economic burden can also be calculated by currency. The loss of income is only one portion of the health loss, and thus, it is an indirect economic burden in a narrow sense. The economic burden also contains invisible economic burden, which cannot be demonstrated by income. For example, the loss of life quality due to hypertension, such as dizziness, headache, nausea and other discomfort, and the inconvenience placed on daily activities due to hypertension, can be defined as invisible or indirect economic burden. However, it is very hard to measure the loss of life quality because it is closely related to people's ability to pay. In practice, the invisible economic burden described by the patients themselves can be easily confused with the loss of income cause by hypertension. Therefore, invisible economic burden is hardly mentioned in recent research. In this blue paper, the economic burden of hypertension only contains direct economic burden, indirect is described in a narrow sense, and the invisible economic burden is excluded. Since the latest statistical data, such as population, morbidity of hypertension, and price index are recorded in 2013, all the economic burden is calculated with the price in 2013, and the data in published research are discounted to 2013 prices in accordance with the consumers' price index to calculate the economic burden in 2013. Due to the fact that there is no nation-wide research on the economic burden of hypertension in China, all data on economic burden in this blue paper are based on the latest provincial samples. After comparing the provincial and national data, the national adjustment coefficient and the national economic burden of hypertension are calculated.
Previous studies were conducted in China on the disease burden and economic burden of hypertension. The economic burden of hypertension was calculated by the Statistics and Information Center of the former Ministry of Health on the basis of the data from the National Health Service inquiry in 2003 and the death registration and reporting system of the former Health Ministry of China. In 2003, the total economic burden of hypertension was 62.25 billion yuan, which was in the third place, right after malignant tumors and cerebral vascular diseases. The direct and indirect economic burden in 2013 was 38.39 billion yuan and 23.87 billion yuan (occupying 61.7% and 38.3%, respectively). [60] The 2013 National Health Service data had not yet been published, and thus, no research is available on economic burden based on its data.
The direct medical costs of hypertension include the costs of outpatient service, inpatient service and drugstore purchasing. According to the latest research, in 2011 in Shandong Province, of every patient with hypertension, the average costs of outpatient service, inpatient service, and drugstore purchasing were 364 yuan, 135 yuan, and 226 yuan, respectively. The total costs were 725 yuan.
[61] The national consumers' price index elevated by 5% from the year 2011-2013. [62] Therefore, the average direct medical cost of every patient with hypertension in Shandong Province in 2013 was calculated as 761 yuan. According to the statistics yearbook of health and family planning in 2014, the latest per capita medical cost of Shandong Province was 1991.65 yuan while the national average medical cost was 2067.67 yuan, and the national adjustment index was 1.04. [63] Therefore, the national average direct medical cost on hypertension after adjustment was 791 yuan. In 2013, the morbidity rate of hypertension was 24%, and there were 266 million patients with hypertension. [64] The direct medical cost of hypertension, which equals the average per capita direct medical burden multiplied by the total number of patients, was 210.4 billion yuan. Studies have shown that during the treatment of hypertension, the average loss of working time was 3.53 days. [65] Since there were 266 million patients with hypertension in 2013 in China, and the daily Per Capita Gross Domestic Product was 162 yuan, the loss of income due to the loss of working time was 152.1 billion yuan during the treatment of hypertension. Studies have shown that in 2006 the average cost of transportation for medical services of every patient was 52.12 yuan; the average nutrition fees were 31.47 yuan. The national consumers' price index was elevated by 26% from 2006 to 2013. Therefore, the average cost for transportation and nutrition fees in 2013 was 65.57 yuan and 39.65 yuan, respectively. With the population of national hypertension patients at 266 million, the total transportation and nutrition fees were 17.5 billion yuan and 10.5 billion yuan, respectively. In 2013 the total cost of working loss, transportation, and nutrition fees due to the treatment of hypertension was 180.1 billion yuan. The direct economic burden was 390.5 billion yuan. The cost of outpatient services was 27% of the total direct economic burden while the cost of inpatient services was 10%. The cost of drugstore purchasing was 17% while the cost of direct nonmedical service was 46%. The indirect economic burden of hypertension contains two parts: the loss of income due to the disease and the loss of income due to death. The loss of income due to the disease equals the average loss of working time for each year of patients with hypertension multiplied by the daily per capita GDP then multiplied by the total number of patients with hypertension in China. Research has shown that the average loss of working time due to hypertension was 4.42 days. In 2013, Chinas per capita GDP was 41,908 yuan. With monthly working days as 21.4 days, daily per capital GDP in 2013 as 41,908 yuan and 266 million patients with hypertension in 2013, the loss of income due to hypertension was 190.5 billion yuan. The loss of income due to death can be calculated as years of potential life cost multiplied by yearly per capita GDP. Research has shown that the age-adjusted years potential life lost was 1.4 years per 1000 people. [66] The population in China in 2013 was 1.361 billion yuan. With the population in 2013 and per capita GDP in 2013, the indirect economic burden due to death with hypertension in 2013 was 79.9 billion yuan. Adding the two parts together, the indirect economic burden in 2013 was 270.4 billion yuan, with 70% attributed to income loss caused by the disease and the other one taking up 30%.
Adding the direct and indirect economic burden together, the total economic burden of hypertension in 2013 was 660.9 billion yuan, with 2485 yuan for each patient with hypertension. The direct part took up 31.85% of the total economic burden. In 2013, the total cost of health in China was 3186.9 billion yuan, with the direct medical cost of hypertension taking up 6.61%. Table 4 shows the lists of all kinds of economic burden calculated by the price in 2013 including the per capita economic burden and the nationwide total economic burden.
the health econoMy effect of the pRevention and tReatMent of hypeRtension
In a 2015 study, the cardiovascular disease (CVD) Policy-Model China was adopted to simulate the health economy of the prevention and treatment of hypertension. The effect of reducing cardiovascular incidents by lowering high blood pressure among adults aging 35-84 from the year 2015-2025 was estimated in this study. According to the National Essential Medicine List, the treatment costs of hypertension and other CVDs were assessed, and the health benefit was illustrated by the term QALYs (quality-adjusted life years [QALYs] , is a comprehensive index which assesses the effect of health policies by the life quality as well as the survival time. One QALY means healthy living for 1 year).
Research have shown that, according to the current basis, if all of the patients with CVDs could be treated with anti-hypertension therapies, there would be a decrease of 1.11 billion adverse cardiovascular events every year (0.9 billion events of stroke Further research has shown the outcome of two different strategies. The first strategy is to expand the population of patients who receive anti-hypertension therapies from patients with mere CVDs to those with hypertension over stage 2 without any history of CVDs. Although the medical costs increase, with the average increase of one QALY, the medical costs increase by 32,000 yuan, which is lower than 38,400 yuan calculated by the per capita GDP of 2015. It means from the aspect of health economy, if all patients with CVDs and those with hypertension at Stages 1 and 2 without any history of CVDs could be treated with anti-hypertension therapies, more health benefits can be delivered through lower medical costs, which is a health policy with high cost-effectiveness. The second strategy is to expand the population of patients to those with hypertension at Stages 1 and 2. In this strategy, with the average increase of one QALY, the medical costs increase by 47,000 yuan. This strategy is currently successfully implemented in Beijing, Shanghai, Guangzhou, and other districts known to be well developed in economy and health with high cost-effectiveness.
This research shows that the public health service and patient education with anti-hypertension drugs according to the National Essential Medicine List will have evident advantages of cost-effectiveness and health benefits in the prevention and treatment of CVDs. We should increase our efforts in the screening and prevention of hypertension among patients over 35 years old, improve the compliance of patients by stabilizing the price of drugs and gradually increase the basic medical security of patients with hypertension of Stages 1 and 2.
cuRRent situation and pRobleMs 1 . The disease burden of hypertension in China in 2010 is as follows. The death population caused by hypertension was 2.043 million. The DALY of Chinese population caused by hypertension was 37.94 million, with the years lost due to dying early (YLL) at 2.37 million, and the YLD at 25.57 million, which accounts for 12% of the total DALYs. Nearly 78.3% of the DALYs were caused by disability in patients who survived and 21.7% were caused by dying early 2. In 2013, the total cost on health in China was 3186.9 billion yuan, with the direct medical cost of hypertension at 210.4 billion yuan (6.61%). The average direct medical cost was 791 yuan, with outpatient department taking up 50%, inpatient taking up 19%, and drugstore purchasing taking up 31% 3. The current research has shown that if all patients with CVDs could be treated with anti-hypertension therapies, there would be a decrease of 1.11 billion adverse cardiovascular events every year (0.9 billion events of stroke and 0.21 billion events of MI), and the health benefits would increase by 80,000 QALYs. If all patients with hypertension at Stages 1 and 2 (with or without any history of CVDs) could be treated with antihypertension therapies, there would be a decrease of 8.03 billion adverse cardiovascular events every year (6.90 billion events of stroke and 1.13 billion events of MI), and the health benefits would increase by 1.18 million QALYs 4. The source of current data on the health economy of hypertension in China is derived merely from the Chinese CVD policy model. The actual health economy effectiveness of different projects on prevention and treatment of hypertension is still lacked. There is also no comparison among the economy of different drugs. suGGestions 1. To allocate health resources reasonably and pay more attention to the prevention and treatment of hypertension and other related diseases 2. To emphasize an early staged and continues treatment of hypertension with or without the presence of CVDs 3. If conditions permit, there should be an analysis of different projects on the prevention and treatment of hypertension and comparisons of the economic differences of antihypertension drugs, to assess the effect of low-cost antihypertension drugs recommended by the National Essential Medicine List on the prevention and treatment of CVDs 4. We should increase our efforts in the screening and prevention of hypertension among patients over 35 years old, improve the compliance of patients by stabilizing the price of drugs, and gradually increase the basic medical security of patients with hypertension of Stages 1 and 2.
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